Reading MYGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MYGN free→Reading MYGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MYGN free→QuarterlyIQ Insights · MYGN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing primarily concerns stockholder approvals for equity incentive plans and amendments to existing plans.
Results of Operations and Financial Condition. On May 5, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended March 31, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…
Results of Operations and Financial Condition. On February 23, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includ…
Results of Operations and Financial Condition. On January 12, 2026, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue for the quarter and full year ended December 31, 2025. The Company also introduced full year 2026 financial guidance. In addition, the Company is announcing certain preliminary volume information for the full year ended December 31, 2025. Specifically, the Company expects total test volumes in 2025 of approximately 1.5 million, a 1…
Results of Operations and Financial Condition. On November 3, 2025, Myriad Genetics, Inc. (“Myriad”) furnished a Current Report on Form 8-K that included a press release reporting financial results for the three months ended September 30, 2025 (the "Original Form 8-K"). Myriad is filing this Amendment No. 1 on Form 8-K/A to amend the Original Form 8-K solely to correct the amount shown for Cash, cash equivalents, and restricted cash at beginning of the period for the three months ended Septem…
Results of Operations and Financial Condition. On November 3, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includin…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2025, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Scott J. Leffler, the Company’s former Chief Financial Officer. As previously disclosed, the Company announced Mr. Leffler’s departure as Chief Financial Officer of the Company, effective August 15, 2…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Natalie Munk as Principal Accounting Officer On September 29, 2025, Natalie Munk, the Senior Vice President, Chief Accounting Officer and principal accounting officer of Myriad Genetics, Inc.’s (the “Company”), provided notice of her resignation from the Company, effective on October 24, 2025. Ms. Munk’s departure is not a result of an…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Scott J. Leffler as Chief Financial Officer On August 18, 2025, Myriad Genetics, Inc. (the “Company”) announced that, effective August 15, 2025, Scott J. Leffler no longer serves as Chief Financial Officer of the Company. Mr. Leffler is expected to remain as a non-executive employee of the Company for an interim period to assist in the…
Results of Operations and Financial Condition. On August 5, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry into a Material Definitive Agreement. On July 31, 2025 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (in such capacity, “Administrative Agent”) and as initial lender, consisting of a $200 million term loan credit facility with an initial term loan (the “Initial Loan”) in a maximum p…
Other Events. On July 31, 2025, the Company issued a press release announcing the entry into the Credit Agreement which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers As reported below in Item 5.07, Myriad Genetics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company's stockholders approved an amendment to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2017 Plan”), which increased the aggregate number of shares…
Results of Operations and Financial Condition. On May 6, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended March 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Paul J. Diaz and Appointment of Samraat S. Raha as President, Chief Executive Officer and Director As part of Myriad Genetics, Inc.’s (the “Company’s”) ongoing succession planning process, Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and…
Results of Operations and Financial Condition. On February 24, 2025, Myriad Genetics, Inc. ("Myriad" or the “Company”) announced its financial results for the three months ended December 31, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Results of Operations and Financial Condition. On January 15, 2025, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue, loss per share and adjusted earnings per share results for the quarter and full year ended December 31, 2024 and cash and cash equivalents as of December 31, 2024. The Company also introduced full year 2025 financial guidance. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by referen…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.